Among patients with symptomatic obstructive hypertrophic cardiomyopathy, treatment with aficamten led to a greater increase in peak oxygen consumption than placebo at 6 months.
The New England Journal of Medicine: Search Results in Cardiology
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
